MyFinsight
Home
Blog
About
Proceeds from exercise of
awards under equity...
$15,005K
(222.55%↑ Y/Y)
Net cash provided by
(used in) financing...
$14,984K
(800.51%↑ Y/Y)
Canceled cashflow
$21K
Net decrease in
cash, cash...
-$186,096K
(-477.54%↓ Y/Y)
Canceled cashflow
$14,984K
Maturities and sales of
marketable securities
$197,032K
(-39.18%↓ Y/Y)
Stockbased compensation
expense
$22,915K
(-54.67%↓ Y/Y)
Non-cash interest
expense related to...
$5,941K
Deferred research and
development funding...
$4,859K
(-69.96%↓ Y/Y)
Depreciation and
amortization
$3,569K
(-33.54%↓ Y/Y)
Accruals and other
current liabilities
$3,288K
(123.24%↑ Y/Y)
Right-of-use asset
amortization for finance...
$915K
(-49.11%↓ Y/Y)
Other non-current
assets
-$396K
(86.90%↑ Y/Y)
Accounts payable
$227K
(627.91%↑ Y/Y)
Payments for finance
lease right-of-use...
$21K
(-99.69%↓ Y/Y)
Net cash provided by
(used in) investing...
-$104,078K
(-158.91%↓ Y/Y)
Net cash used in
operating activities
-$97,002K
(53.09%↑ Y/Y)
Canceled cashflow
$197,032K
Canceled cashflow
$42,110K
Purchases of marketable
securities
$271,505K
(96.85%↑ Y/Y)
Net loss
-$127,553K
(50.39%↑ Y/Y)
Cash paid to acquire
finite-lived intangible...
$28,800K
Purchases of property and
equipment
$805K
(-91.40%↓ Y/Y)
Inventory
$4,139K
Accounts receivable, net
$3,927K
Net accretion of
discounts on marketable...
$1,445K
(-78.06%↓ Y/Y)
Non-cash adjustment to
operating lease expense
$1,209K
(-44.05%↓ Y/Y)
Other non-cash items
$517K
Prepaid expenses and
other current assets
$322K
(-91.18%↓ Y/Y)
Back
Back
Cash Flow
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)
source: myfinsight.com